This clinical trial focuses on treating lupus nephritis, a kidney inflammation that occurs in people with lupus. The study compares two different treatment approaches. The first approach uses mycophenolate mofetil (MMF) together with oral corticosteroids, while the second approach combines MMF with obinutuzumab (Gazyvaro) without additional oral corticosteroids.
The purpose of this research is to determine if treating patients with obinutuzumab and MMF without additional oral corticosteroids works as well as the traditional treatment using corticosteroids and MMF. The study measures how well the kidneys respond to treatment after 52 weeks. During the treatment period, patients receive their assigned medications according to a specific schedule. Obinutuzumab is given through an intravenous infusion, while MMF is taken as oral tablets.
Throughout the study, doctors monitor kidney function by checking protein levels in urine and measuring how well the kidneys filter blood. They also track any side effects that may occur during treatment. Some patients may also receive other medications like azathioprine or prednisolone as part of their treatment plan.
France 
